P B Clifton-Bligh1, M-L Nery2, R J Clifton-Bligh1, S Visvalingam3, G R Fulcher1, K Byth4, R Baber5. 1. 1] Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia [2] Northern Clinical School, University of Sydney, St Leonards, NSW, Australia. 2. Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia. 3. Menopause Clinic, Royal North Shore Hospital, St Leonards, NSW, Australia. 4. NHMRC Clinical Trials Centre, University of Sydney, St Leonards, NSW, Australia. 5. 1] Northern Clinical School, University of Sydney, St Leonards, NSW, Australia [2] Menopause Clinic, Royal North Shore Hospital, St Leonards, NSW, Australia.
Abstract
BACKGROUND: Although postmenopausal combined hormone replacement therapy reduces the risk of hip fracture, long-term use may be associated with an increased risk of breast cancer, and in women more than 10 years after menopause it is associated with an increased risk of cardiovascular disease. Isoflavones, because of preferential binding to estrogen receptor beta, may retain the beneficial effects on bone but lessen the adverse effects on the breast. OBJECTIVE: The objective of this study was to study the effects of an isoflavone obtained from red clover (Rimostil) on bone mineral density, and on low-density lipoprotein (LDL) cholesterol. DESIGN: In a double-blind, randomized, placebo-controlled trial, 50 mg of Rimostil was given to women who were menopausal for at least 1 year. Bone mineral density of the spine, femoral neck and forearm and serum LDL cholesterol were measured at baseline and at 6-month intervals. The duration of follow-up was 2 years. RESULTS: There was no beneficial effect of Rimostil on bone density at any site. There was a 12% fall in serum LDL cholesterol in the Rimostil-treated arm, which was significantly greater than the 2% drop seen in the control arm (P=0.005).
RCT Entities:
BACKGROUND: Although postmenopausal combined hormone replacement therapy reduces the risk of hip fracture, long-term use may be associated with an increased risk of breast cancer, and in women more than 10 years after menopause it is associated with an increased risk of cardiovascular disease. Isoflavones, because of preferential binding to estrogen receptor beta, may retain the beneficial effects on bone but lessen the adverse effects on the breast. OBJECTIVE: The objective of this study was to study the effects of an isoflavone obtained from red clover (Rimostil) on bone mineral density, and on low-density lipoprotein (LDL) cholesterol. DESIGN: In a double-blind, randomized, placebo-controlled trial, 50 mg of Rimostil was given to women who were menopausal for at least 1 year. Bone mineral density of the spine, femoral neck and forearm and serum LDL cholesterol were measured at baseline and at 6-month intervals. The duration of follow-up was 2 years. RESULTS: There was no beneficial effect of Rimostil on bone density at any site. There was a 12% fall in serum LDL cholesterol in the Rimostil-treated arm, which was significantly greater than the 2% drop seen in the control arm (P=0.005).
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Stavroula Kousteni; Maria Almeida; Li Han; Teresita Bellido; Robert L Jilka; Stavros C Manolagas Journal: Mol Cell Biol Date: 2006-12-11 Impact factor: 4.272
Authors: Lucy Cooper; Phillip B Clifton-Bligh; M Liza Nery; Gemma Figtree; Stephen Twigg; Emily Hibbert; Bruce G Robinson Journal: Am J Clin Nutr Date: 2003-05 Impact factor: 7.045
Authors: G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson Journal: Endocrinology Date: 1998-10 Impact factor: 4.736
Authors: Tatiana V Kirichenko; Vasily N Sukhorukov; Alexander M Markin; Nikita G Nikiforov; Ping-Yen Liu; Igor A Sobenin; Vadim V Tarasov; Alexander N Orekhov; Gjumrakch Aliev Journal: Front Pharmacol Date: 2020-04-08 Impact factor: 5.810
Authors: Anne Cathrine Thorup; Max Norman Lambert; Henriette Strøm Kahr; Mette Bjerre; Per Bendix Jeppesen Journal: Evid Based Complement Alternat Med Date: 2015-07-21 Impact factor: 2.629